Association of 1,5-Anhydroglucitol with Diabetes and Microvascular Conditions E. Selvin, A.M. Rawlings, M. Grams, R. Klein, M. Steffes, and J. Coresh November.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Association of 1,5-Anhydroglucitol with Diabetes and Microvascular Conditions
E. Selvin, A.M. Rawlings, M. Grams, R. Klein, M. Steffes, and J. Coresh
Participants from the Atherosclerosis Risk in Communities (ARIC) Study, attending visit 2 (1990-1992) for incident analyses, or visit 3 (1993-1995) for retinopathy analyses
1,5-AG measured in stored serum samples GlycoMarkTM assay using the Roche Modular P800 system Inter-assay CV = 5%, reliability coefficient for 610 masked
duplicate sample pairs = 0.99 1,5-AG categorized into a 5-level variable: Among persons without diabetes: ≥10, <10 μg/mL Among persons with diabetes: ≥10, 10-6, <6 μg/mL
Statistical analysis Adjusted Cox and logistic regression models
a Model 1: age, race-center, sex b Model 2: variables in model 1 + LDL cholesterol, HDL -cholesterol, triglycerides, body mass index, waist-to-hip ratio, mean systolic blood pressure, blood pressure–lowering medication use, family history of diabetes, education, drinking status, smoking status, physical activity index.c Model 3: variables in model 2 + Hb A1c (per %-point)d Model 4: variables in model 2 + fasting glucose (per 1 mg/dL)
Table 2 (cont) – Incident CKD and DiabetesTable 2 (cont) – Incident CKD and Diabetes
a Model 1: age, race-center, sex b Model 2: variables in model 1 + LDL cholesterol, HDL -cholesterol, triglycerides, body mass index, waist-to-hip ratio, mean systolic blood pressure, blood pressure–lowering medication use, family history of diabetes, education, drinking status, smoking status, physical activity index.c Model 3: variables in model 2 + Hb A1c (per %-point)d Model 4: variables in model 2 + fasting glucose (per 1 mg/dL)
1,5-AG was most strongly associated with prevalent retinopathy. What are some likely explanations for the differences in magnitude of associations of 1,5-AG with the clinical outcomes in this study?
Figure 1. Adjusted associations for baseline 1,5-anhydroglucitol with prevalent retinopathy (ORs) and incident CKD and incident diabetes (HRs) in the overall population.Frequency histograms for 1,5-AG are shown separately for persons with diagnosed diabetes (dark grey bars) and without diagnosed diabetes (light grey bars).
What do you notice about the distribution of 1,5-AG from Figure 1? How might this influence interpretation of results and utility of 1,5-AG as a biomarker?
Figure 2. Prevalence of retinopathy (A) and 20-year cumulative incidence of CKD (B) by categories of 1,5-AG (<10 g/mL, >10 g/dL) within categories of glycemic control (HbA1c <7%, HbA1c >7%) among persons with diagnosed diabetes at baseline. Vertical bars are 95% CIs.